The Burkitt lymphoma market is expected to experience significant growth across the seven major markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. This growth is driven by several factors, including the increasing prevalence of the disease, advancements in diagnostic capabilities, and a strong pipeline of new therapies. Key Burkitt lymphoma companies, such as Jazz Pharmaceuticals, Xencor, ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others, are leading innovation and addressing unmet treatment needs.
DelveInsight's latest comprehensive research report, "Burkitt Lymphoma Market Insight, Epidemiology And Market Forecast — 2032," presents critical insights into the evolving Burkitt lymphoma market landscape across 7MM. The report highlights significant growth in the Burkitt lymphoma treatment market during the forecast period of 2019-2032, driven by increased awareness, improved diagnostic capabilities, and the emergence of novel therapeutics.
Download the report to understand which factors are driving the Burkitt lymphoma therapeutic market @ Burkitt lymphoma Market Trends
Burkitt lymphoma is an aggressive form of non-Hodgkin B-cell lymphoma that begins in B-cells. The disease is frequently associated with Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), and chromosomal translocations causing overexpression of the oncogene c-myc. While the exact cause remains unknown, geographical factors influence risk patterns, with malaria exposure being significant in endemic regions like Africa and HIV representing the primary risk factor elsewhere. The World Health Organization classifies Burkitt lymphoma into three distinct types: Endemic (primarily affecting African children), Sporadic (occurring globally), and Immunodeficiency-associated (most common in people with HIV).
According to epidemiological data cited in the report, Burkitt lymphoma represents approximately half of all malignant non-Hodgkin lymphomas in children and around 2% in adults across Europe and North America, with males being disproportionately affected compared to females. Further research indicates that in children under 18 years old, the incidence is approximately 3-6 cases per 100K children annually. For sporadic Burkitt lymphoma, the estimated annual incidence is 4 per 1 million children under 16 years of age and around 2.5 per 1 million in adults. The immunodeficiency-associated variant has a notably higher incidence of 22 per 100K in the United States.
Discover evolving trends in Burkitt lymphoma patient pool forecasts @ Burkitt lymphoma Epidemiology Analysis
The DelveInsight report also discusses the current and future treatment strategies for Burkitt lymphoma. The existing treatment market for Burkitt lymphoma primarily focuses on intravenous chemotherapy regimens, utilizing agents such as cyclophosphamide, cytarabine, doxorubicin, etoposide, methotrexate, and vincristine. RITUXAN (GeneNtech/Biogen) remains the only approved drug used in combination with various chemotherapy protocols, including R-CODOX-M, R-IVAC, and DA-EPOCH-R. In some cases, surgical intervention may be necessary to address intestinal complications. The overall cure rate for sporadic Burkitt lymphoma approaches an impressive 90% in pediatric and young adult populations.
The Burkitt lymphoma drugs development market shows promising activity with several emerging therapies in the pipeline. Notable among these is ADCT-402 (ADC Therapeutics), an antibody-drug conjugate targeting CD19 on B-cells. PC-002 (Cothera Biosciences) is another investigational agent that works by inhibiting survivin expression in tumor cells. Other notable candidates are CPX-351 (Jazz Pharmaceuticals) and Plamotamab (Xencor). Key companies advancing the Burkitt lymphoma therapeutics market include ADC Therapeutics, Cothera Bio, Merck, and Cornerstone Pharmaceuticals, among others.
A robust pipeline of several therapies, including gene-modified cell therapies and small molecules, is under development. In October 2024, the FDA granted Fast Track designation to Cothera Bioscience's clinical program PC-002 for the treatment of relapsed or refractory Burkitt Lymphoma. The clinical outcomes and prognostic implications of rituximab in pediatric B-cell non-Hodgkin lymphoma, including Burkitt lymphoma, which represented 53.2% of cases in the study, show positive results as of March 2025. These recent developments underscore the progress toward improving outcomes for Burkitt lymphoma.
Unlock which emerging Burkitt lymphoma drug is expected to capture the largest market share in 7MM by 2034. Visit the Burkitt lymphoma Market Insights
According to DelveInsight's analysis, the Burkitt lymphoma market faces several challenges, including delayed diagnosis and limited approved therapeutic options. However, the Burkitt lymphoma market shows substantial growth, driven by increased disease awareness, enhanced healthcare spending, and the introduction of novel targeted therapies with improved efficacy profiles. The robust pipeline of innovative treatments and growing research focus on addressing unmet needs position the Burkitt lymphoma treatment market for significant expansion across the 7MM.
Table of Contents
| 1. | Report Introduction |
| 2. | Executive Summary of Burkitt Lymphoma |
| 3. | SWOT Analysis of Burkitt Lymphoma |
| 4. | Burkitt Lymphoma: Patient Share (%) Overview at a Glance |
| 5. | Burkitt Lymphoma: Market Overview (%) at a Glance |
| 6. | Disease Background and Overview |
| 7. | Epidemiology and Patient Population |
| 8. | Country-Specific Patient Population of Burkitt Lymphoma |
| 9. | Current Treatment and Medical Practices |
| 10. | Patient Journey |
| 11. | Unmet Needs |
| 12. | Key Endpoint of Clinical Trials |
| 13. | Emerging Therapies |
| 14. | Conjoint Analysis of Burkitt Lymphoma Therapies |
| 15. | Burkitt Lymphoma: Market Size of 7MM |
| 16. | Country-Wise Market Analysis (2019-2032) |
| 17. | Market Access and Reimbursement of Burkitt Lymphoma |
| 18. | Market drivers |
| 19. | Market barriers |
| 20. | Appendix |
| 21. | DelveInsight Capabilities |
| 22. | Disclaimer |
| 23. | About DelveInsight |
Related Reports
B-cell Lymphoma Pipeline Insight
B-cell Lymphoma Pipeline Insight provides comprehensive insights about the B-cell Lymphoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the B-cell Lymphoma companies, including Lisocabtagene maraleucel, Hoffmann-La Roche (ROG), Nektar Therapeutics (NKTR), Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation (INCY), ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech, CARGO Therapeutics (CRGX), Chia Tai Tianqing Pharmaceutical Group, SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics (IOVA), Guangzhou Excelmab, Y-mAbs Therapeutics (YMAB), TG Therapeutics, Sutro Biopharma, AbbVie (ABBV), Aleta Biotherapeutics, Janssen Research & Development, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, and HUTCHMED (HCM) among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
